Talphera
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 15
- Market Cap
- $16.4M
- Introduction
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Clinical Trials
18
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
- Conditions
- Acute Kidney Injury
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 166
- Registration Number
- NCT06150742
- Locations
- 🇺🇸
Wake Forest, Winston-Salem, North Carolina, United States
Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
- Conditions
- Moderate-to-severe Acute Pain
- Interventions
- Drug: Zalviso™ 15 mcg
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 320
- Registration Number
- NCT02662764
- Locations
- 🇺🇸
Eliza Coffee Memorial Hospital, Florence, Alabama, United States
🇺🇸Shoals Medical Trials, Sheffield, Alabama, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
- Conditions
- Acute Moderate-to-severe Pain
- Interventions
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 140
- Registration Number
- NCT02662556
- Locations
- 🇺🇸
HD Research, Houston, Texas, United States
🇺🇸Research Concepts, Houston, Texas, United States
Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
- Conditions
- Moderate-to-severe Acute Pain
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 76
- Registration Number
- NCT02447848
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
🇺🇸Hermann Memorial Medical Center, Houston, Texas, United States
🇺🇸Ben Taub General Hospital, Houston, Texas, United States
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
- Conditions
- Post-Operative Pain
- Interventions
- Drug: Placebo Tablet
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 161
- Registration Number
- NCT02356588
- Locations
- 🇺🇸
Shoals Medical Trials, Inc, Sheffield, Alabama, United States
🇺🇸Lotus Clinical Research, Pasadena, California, United States
🇺🇸Victory Medical Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Talphera's Niyad Receives FDA Agreement for Enrollment Acceleration in NEPHRO CRRT Trial
Talphera has reached an agreement with the FDA for a Prior Approval Supplement (PAS) review to reduce the number of patients in the NEPHRO CRRT study.